

- **HEPATIC IMPAIRMENT** Manufacturer advises caution in mild impairment; avoid in moderate to severe impairment (no information available).
- **RENAL IMPAIRMENT** Manufacturer advises caution in mild or moderate impairment.  
**Dose adjustments** Max. daily dose 30 mg if eGFR less than 30 mL/minute/1.73 m<sup>2</sup>.
- **PRESCRIBING AND DISPENSING INFORMATION** The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Modified-release capsule**

CAUTIONARY AND ADVISORY LABELS 3, 25

▶ **Detrunorm XL** (Advanz Pharma)**Propiverine hydrochloride 30 mg** Detrunorm XL 30mg capsules |

28 capsule [PoM] £24.45 DT = £24.45

**Propiverine hydrochloride 45 mg** Detrunorm XL 45mg capsules |

28 capsule [PoM] £27.90 DT = £27.90

**Tablet**

CAUTIONARY AND ADVISORY LABELS 3

▶ **Propiverine hydrochloride (Non-proprietary)****Propiverine hydrochloride 15 mg** Propiverine 15mg tablets |

56 tablet [PoM] £25.42 DT = £22.78

▶ **Detrunorm** (Advanz Pharma)**Propiverine hydrochloride 15 mg** Detrunorm 15mg tablets |

56 tablet [PoM] £18.00 DT = £22.78

F 820

**Solifenacin succinate**

13-May-2020

● **INDICATIONS AND DOSE****Urinary frequency | Urinary urgency | Urinary incontinence**▶ **BY MOUTH**

- ▶ **Adult:** 5 mg once daily, increased if necessary to 10 mg once daily

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

- ▶ Manufacturer advises max. dose 5 mg daily with concurrent use of potent inhibitors of CYP3A4; avoid concurrent use in patients who also have moderate hepatic impairment or severe renal impairment.

- **CAUTIONS** Neurogenic bladder disorder · susceptibility to QT-interval prolongation
- **INTERACTIONS** → Appendix 1: solifenacin
- **SIDE-EFFECTS**
  - ▶ **Common or very common** Gastrointestinal discomfort
  - ▶ **Uncommon** Cystitis · dry eye · dry throat · fatigue · gastrointestinal disorders · nasal dryness · peripheral oedema · taste altered · urinary tract infection
  - ▶ **Rare or very rare** Hallucination
  - ▶ **Frequency not known** Anaphylactic reaction · appetite decreased · arrhythmias · delirium · dysphonia · glaucoma · hyperkalaemia · liver disorder · muscle weakness · QT interval prolongation · renal impairment
- **PREGNANCY** Manufacturer advises caution—no information available.
- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution in moderate impairment (risk of increased half-life); avoid in severe impairment (no information available).  
**Dose adjustments** Manufacturer advises maximum 5 mg daily in moderate impairment.
- **RENAL IMPAIRMENT**  
**Dose adjustments** Max. 5 mg daily if eGFR less than 30 mL/minute/1.73 m<sup>2</sup>.
- **PRESCRIBING AND DISPENSING INFORMATION** The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Oral solution**▶ **Solifenacin succinate (Non-proprietary)****Solifenacin succinate 1 mg per 1 ml** Solifenacin 5mg/5ml oral solution sugar free sugar-free | 150 ml [PoM] £22.50**Oral suspension**▶ **Vesicare** (Astellas Pharma Ltd)**Solifenacin succinate 1 mg per 1 ml** Vesicare 1mg/ml oral suspension sugar-free | 150 ml [PoM] £27.62 DT = £27.62**Tablet**

CAUTIONARY AND ADVISORY LABELS 3

▶ **Solifenacin succinate (Non-proprietary)****Solifenacin succinate 5 mg** Solifenacin 5mg tablets |

30 tablet [PoM] £27.62 DT = £3.54 | 250 tablet [PoM] £29.50-£230.17

**Solifenacin succinate 10 mg** Solifenacin 10mg tablets |

30 tablet [PoM] £35.91 DT = £4.48 | 100 tablet [PoM] £119.70 |

250 tablet [PoM] £45.99-£299.25

▶ **Vesicare** (Astellas Pharma Ltd)**Solifenacin succinate 5 mg** Vesicare 5mg tablets | 30 tablet [PoM]

£27.62 DT = £3.54

**Solifenacin succinate 10 mg** Vesicare 10mg tablets |

30 tablet [PoM] £35.91 DT = £4.48

F 820

**Tolterodine tartrate**

20-Jan-2020

● **INDICATIONS AND DOSE****Urinary frequency | Urinary urgency | Urinary incontinence**▶ **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**

- ▶ **Adult:** 2 mg twice daily, reduced if not tolerated to 1 mg twice daily

▶ **BY MOUTH USING MODIFIED-RELEASE CAPSULES**

- ▶ **Adult:** 4 mg once daily

- **CAUTIONS** History of QT-interval prolongation
- **INTERACTIONS** → Appendix 1: tolterodine
- **SIDE-EFFECTS**
  - ▶ **Common or very common** Abdominal pain · bronchitis · chest pain · diarrhoea · dry eye · fatigue · gastrointestinal disorders · paraesthesia · peripheral oedema · vertigo · weight increased
  - ▶ **Uncommon** Arrhythmia · heart failure · memory loss · nervousness
  - ▶ **Frequency not known** Hallucination
- **PREGNANCY** Manufacturer advises avoid—toxicity in animal studies.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution (risk of increased exposure).  
**Dose adjustments** For immediate-release medicines, manufacturer advises dose reduction to 1 mg twice daily.  
For modified-release capsules, manufacturer advises dose reduction to 2 mg once daily.
- **RENAL IMPAIRMENT** Manufacturer advises caution (risk of increased exposure).  
**Dose adjustments** For immediate-release medicines, manufacturer advises dose reduction to 1 mg twice daily if GFR less than or equal to 30 mL/minute.  
For modified-release capsules, manufacturer advises dose reduction to 2 mg once daily if GFR less than or equal to 30 mL/minute.
- **PRESCRIBING AND DISPENSING INFORMATION** The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.